Magnus Financial Group LLC Has $471,000 Stock Position in BioHarvest Sciences Inc. $BHST

Magnus Financial Group LLC lowered its position in BioHarvest Sciences Inc. (NASDAQ:BHST) by 2.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,000 shares of the company’s stock after selling 1,733 shares during the period. Magnus Financial Group LLC owned about 0.43% of BioHarvest Sciences worth $471,000 as of its most recent SEC filing.

Separately, True North Advisors LLC grew its stake in BioHarvest Sciences by 7.6% in the first quarter. True North Advisors LLC now owns 44,391 shares of the company’s stock valued at $275,000 after acquiring an additional 3,120 shares during the period.

BioHarvest Sciences Price Performance

Shares of BioHarvest Sciences stock opened at $11.00 on Friday. The company has a market capitalization of $180.62 million, a P/E ratio of -15.71 and a beta of 0.68. The business has a 50-day moving average of $8.38 and a two-hundred day moving average of $7.10. BioHarvest Sciences Inc. has a 1 year low of $4.66 and a 1 year high of $12.00.

BioHarvest Sciences (NASDAQ:BHST) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.04). BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. The business had revenue of $8.52 million for the quarter, compared to the consensus estimate of $8.53 million. BioHarvest Sciences has set its Q3 2025 guidance at EPS. On average, equities analysts anticipate that BioHarvest Sciences Inc. will post -0.8 EPS for the current fiscal year.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.